In an article just published in Clinical Leader magazine entitled “How An Australia-First Strategy Cut 63% From Our R&D Spend”, Etira CEO Russell Hayward explains how our strategic decision to conduct clinical trials in Australia has significantly reduced our R&D spending. This innovative approach enables us to accelerate the development of our first-in-class cancer therapy, […]